Latest News

As retatrutide moves toward FDA submission, Jennifer Goldman, PharmD, breaks down the TRIUMPH-1 data—and what it means for patient selection, dose escalation counseling, and positioning within the antiobesity pipeline.

Updated results from a phase 1 study showed that KLN-1010 produced reduced MRD-negative responses in all treated patients with RRMM.

The FDA approved the oral antiviral ensitrelvir (Xocova; Shionogi & Co, Ltd) for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years and older.

Data presented at ASCO 2026 show giredestrant plus palbociclib extends PFS in ER+/HER2– metastatic breast cancer; FDA approval on the horizon.

ASCENT-04 updated data show sacituzumab govitecan plus pembrolizumab extends benefit past progression in PD-L1+ metastatic TNBC.

Final results from the CEPHEUS trial showed that daratumumab plus VRd produced deeper, more durable responses and prolonged survival.

Emerging evidence suggests that some individuals develop nutritional deficiencies during treatment, while others experience biologically driven GLP-1 resistance.

An RNA- and lipid nanoparticle–based platform derived from non-LTR transposons enables stable in vivo CAR T-cell engineering.

Disparities in education access and quality, income level, and race and ethnicity are SDoH that make a major impact on diabetes and its management in the US.

ASCO 2026 data show encorafenib plus cetuximab with FOLFIRI boosts response and PFS in BRAF V600E mCRC, complementing FOLFOX.

Findings presented at the 2026 Joint ASTCT + EBMT Basic and Translational Scientific Meeting offer potential therapeutic targets to reduce GI toxicity and GVHD.

With no new kidney-protective therapies approved in T1D for over three decades, experts break down the clinical significance of finerenone's FDA priority review and what pharmacists need to know.

Phase 3 SARC041 shows abemaciclib sharply extends progression-free survival in advanced dedifferentiated liposarcoma, hinting at a new standard.

The trial met both dual primary end points of pathologic complete response and metastasis-free survival.

ASCO 2026 GLORA tests lisaftoclax as an addition to BTK inhibitors to deepen responses and delay progression in high-risk CLL/SLL.

Seven-year CROWN trial update shows lorlatinib delivers durable progression-free survival and strong brain control in ALK-positive NSCLC.

DREAMM-9 shows belantamab mafodotin in TI NDMM delivers high responses, with longer dosing improving eye safety and quality of life.

Enfortumab vedotin combination delivers lasting complete responses in la/mUC.

ASCO 2026 data show perioperative enfortumab vedotin plus pembrolizumab boosts EFS, OS, and pCR in cisplatin-eligible MIBC.

ASCO 2026: Glofitamab monotherapy shows durable remissions in relapsed mantle cell lymphoma after BTKi, with manageable CRS.

At ASCO 2026, CHRYSALIS-2 data show amivantamab plus lazertinib extends survival in atypical EGFR-mutated NSCLC, reshaping first-line care.